OBJECTIVE: The risk of depression in women is greatest at childbearing age. We sought to examine and explain national trends in antidepressant use in pregnant women. METHODS: This was a cohort study including pregnant women aged 12-55 who were enrolled in Medicaid during 2000-2007. We examined the proportion of women taking antidepressants during pregnancy by patient characteristics (descriptive), by region (mixed-effects model) and over time (interrupted time series). RESULTS: We identified 1,106,757 pregnancies in 47 states; mean age was 23 years, and 60% were nonwhite. Nearly 1 in 12 used an antidepressant during pregnancy. Use was higher for older (11.2% for age ≥30 vs. 7.6% for <30) and white (14.4% vs. 4.0% for nonwhite) women. There was a four- to fivefold difference in rate of antidepressant use among states. Of the 5.3% of women taking antidepressants at conception, 33% and 17% were still on treatment 90 and 180 days, respectively, into pregnancy; an additional 4% began use during pregnancy. Labeled pregnancy-related health advisories did not appear to affect antidepressant use. CONCLUSIONS: Antidepressant use during pregnancy remains high in this population; treatment patterns vary substantially by patient characteristics and region. Comparative safety and effectiveness data to help inform treatment choices are needed in this setting.
OBJECTIVE: The risk of depression in women is greatest at childbearing age. We sought to examine and explain national trends in antidepressant use in pregnant women. METHODS: This was a cohort study including pregnant women aged 12-55 who were enrolled in Medicaid during 2000-2007. We examined the proportion of women taking antidepressants during pregnancy by patient characteristics (descriptive), by region (mixed-effects model) and over time (interrupted time series). RESULTS: We identified 1,106,757 pregnancies in 47 states; mean age was 23 years, and 60% were nonwhite. Nearly 1 in 12 used an antidepressant during pregnancy. Use was higher for older (11.2% for age ≥30 vs. 7.6% for <30) and white (14.4% vs. 4.0% for nonwhite) women. There was a four- to fivefold difference in rate of antidepressant use among states. Of the 5.3% of women taking antidepressants at conception, 33% and 17% were still on treatment 90 and 180 days, respectively, into pregnancy; an additional 4% began use during pregnancy. Labeled pregnancy-related health advisories did not appear to affect antidepressant use. CONCLUSIONS: Antidepressant use during pregnancy remains high in this population; treatment patterns vary substantially by patient characteristics and region. Comparative safety and effectiveness data to help inform treatment choices are needed in this setting.
Authors: Allen A Mitchell; Suzanne M Gilboa; Martha M Werler; Katherine E Kelley; Carol Louik; Sonia Hernández-Díaz Journal: Am J Obstet Gynecol Date: 2011-04-22 Impact factor: 8.661
Authors: Hendrée E Jones; Karol Kaltenbach; Sarah H Heil; Susan M Stine; Mara G Coyle; Amelia M Arria; Kevin E O'Grady; Peter Selby; Peter R Martin; Gabriele Fischer Journal: N Engl J Med Date: 2010-12-09 Impact factor: 91.245
Authors: David A Sclar; Linda M Robison; Jennifer M Schmidt; Kurt A Bowen; Leigh V Castillo; Ambartsum M Oganov Journal: Clin Drug Investig Date: 2012-02-01 Impact factor: 2.859
Authors: Kimberly A Yonkers; Katherine L Wisner; Donna E Stewart; Tim F Oberlander; Diana L Dell; Nada Stotland; Susan Ramin; Linda Chaudron; Charles Lockwood Journal: Gen Hosp Psychiatry Date: 2009 Sep-Oct Impact factor: 3.238
Authors: Patricia M Dietz; Selvi B Williams; William M Callaghan; Donald J Bachman; Evelyn P Whitlock; Mark C Hornbrook Journal: Am J Psychiatry Date: 2007-10 Impact factor: 18.112
Authors: Robert L Davis; David Rubanowice; Heather McPhillips; Marsha A Raebel; Susan E Andrade; David Smith; Marianne Ulcickas Yood; Richard Platt Journal: Pharmacoepidemiol Drug Saf Date: 2007-10 Impact factor: 2.890
Authors: Susan E Andrade; Marsha A Raebel; Jeffrey Brown; Kimberly Lane; James Livingston; Denise Boudreau; Sharon J Rolnick; Douglas Roblin; David H Smith; Mary E Willy; Judy A Staffa; Richard Platt Journal: Am J Obstet Gynecol Date: 2007-10-01 Impact factor: 8.661
Authors: Sonja A Swanson; Sonia Hernandez-Diaz; Kristin Palmsten; Helen Mogun; Mark Olfson; Krista F Huybrechts Journal: Pharmacoepidemiol Drug Saf Date: 2015-06-04 Impact factor: 2.890
Authors: Edênia C Menezes; Relish Shah; Lindsay Laughlin; K Yaragudri Vinod; John F Smiley; Catarina Cunha; Andrea Balla; Henry Sershen; Francisco X Castellanos; André Corvelo; Cátia M Teixeira Journal: J Neurosci Date: 2021-02-03 Impact factor: 6.167
Authors: Paige D Wartko; Noel S Weiss; Daniel A Enquobahrie; K C Gary Chan; Alyssa Stephenson-Famy; Beth A Mueller; Sascha Dublin Journal: Pharmacoepidemiol Drug Saf Date: 2019-07-12 Impact factor: 2.890
Authors: Elizabeth C Ailes; Regina M Simeone; April L Dawson; Emily E Petersen; Suzanne M Gilboa Journal: Birth Defects Res A Clin Mol Teratol Date: 2016-11
Authors: William V Bobo; Richard A Epstein; Rachel M Hayes; Richard C Shelton; Tina V Hartert; Ed Mitchel; Jeff Horner; Pingsheng Wu Journal: Arch Womens Ment Health Date: 2013-10-03 Impact factor: 3.633